First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer First CDK4/6 Inhibitor to Improve Survival in Metastatic Breast Cancer
Ribociclib plus standard-of-care endocrine therapy significantly improved overall survival for younger women with advanced hormone receptor-positive breast cancer vs endocrine therapy alone.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Endocrine Therapy | Hematology | Hormones | Women